Panelists discuss how subcutaneous (SubQ) drug formulations offer practical value by significantly reducing treatment times, easing staffing pressures, and enhancing efficiency in oncology ...

New analyses reinforce long-term benefit of DARZALEX® (daratumumab) subcutaneous-based quadruplet regimen for patients with newly diagnosed multiple myeloma ...

Subcutaneous ICD Ekes Out Favorable Safety Signals 8 Years Into PRAETORIAN Trial — Fewer lead-related complications with subcutaneous ICD versus transvenous ICD ...

A subcutaneous injectable form of nivolumab is available to treat melanoma, non-small cell lung cancer, renal cell cancer, and many other cancers.

Lundbeck has stopped development of a subcutaneous formulation of its migraine drug Lu AG09222 as the Danish drugmaker switches its focus to intravenous delivery after seeing phase 2b data ...

Amneal and Shilpa are releasing Boruzu, a new presentation of bortezomib for ready-to-use subcutaneous administration or intravenous administration. This new ready-to-use oncology product reduces ...

Elotuzumab plus pomalidomide, bortezomib, and dexamethasone showed tolerability in patients with relapsed or refractory multiple myeloma.

Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy Keytruda in the U.S. on October 1, and expects to hit peak adoption ...

The addition of subcutaneous daratumumab to triplet therapy improved outcomes in transplant-ineligible or -deferred multiple myeloma. The regimen reduced risk for disease progression or death by 43%.

Subcutaneous delivery has been used for some time, including for well-known therapies such as trastuzumab (Herceptin), which is used in HER2-positive breast cancer, and bortezomib (Velcade), and ...

Switching from IV to subcutaneous infliximab maintenance therapy is associated with high treatment persistence and a stable disease course and is both effective and safe for patients with IBD.